Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH)

NCT04773964 is registered in ClinicalTrials.gov with Metacrine, Inc. as lead sponsor.

NCT NCT04773964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04773964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2a Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MET642 in Patients With Nonalcoholic Steatohepatitis (NASH)
Lead sponsor
Metacrine, Inc.
Phase
Phase 2
Overall status
Completed
Start date
March 3, 2021
Completion date
December 31, 2022
Enrollment
215 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nash - nonalcoholic steatohepatitis